Cytosorbents Corp CTSO Income Statement

Cytosorbents corp (CTSO)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Sep'11	Jun'11	Sep'10	Jun'10
Revenue:
CytoSorb sales
-	-	-	20,912	-	-	-	17,222	15,062	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other sales
-	-	-	87	-	-	-	200	156	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue
28,465	24,949	24,219	23,867	23,262	22,503	18,870	16,168	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant income
-	-	-	2,247	-	-	-	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Product Sales
-	-	-	-	-	-	-	-	-	-	-	-	9,204	-	7,088	6,017	4,937	4,043	3,419	3,379	3,269	3,135	2,578	1,750	1,214	821	595	405	310	151	63	0	0	0	-	-	-
Grant income
-	-	-	-	-	-	-	-	-	-	-	-	1,626	-	1,116	1,120	930	735	470	326	505	978	1,543	2,092	1,896	1,600	1,552	1,466	1,353	1,191	675	0	0	0	-	-	-
Other revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11	14	17	8	9	6	4	1	0	0	0	0	-	-	-	-	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	10,831	-	8,205	7,137	5,878	4,791	3,904	3,723	3,783	4,122	4,128	3,846	3,113	2,422	2,147	1,872	1,664	1,342	738	0	0	0	-	-	-
Total revenue
-	-	-	23,247	-	-	-	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Cost of revenue
8,010	7,363	7,352	7,708	7,660	7,489	6,923	6,352	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of revenue
-	-	-	-	-	-	-	-	-	-	-	-	4,388	-	3,460	3,135	2,727	2,212	1,738	1,575	1,775	2,133	2,642	2,787	2,320	1,911	1,187	708	518	319	205	0	0	0	-	-	-
Gross margin
20,454	17,585	16,247	15,539	15,110	15,014	14,398	13,015	11,130	9,632	8,037	7,177	6,442	5,574	4,744	4,001	3,151	2,579	2,166	2,147	2,007	1,988	1,485	1,059	792	511	960	1,164	1,145	1,023	532	0	0	0	-	-	-
Other expenses:
Research and development
11,638	12,091	11,011	9,770	8,416	7,723	6,894	5,594	4,476	3,221	2,523	3,052	3,686	4,073	4,372	4,066	3,776	3,871	3,586	3,600	3,146	2,431	1,496	910	1,271	1,738	2,336	2,596	2,603	2,532	2,682	2,983	0	0	0	0	0
Legal, financial and other consulting
2,419	2,462	2,598	2,281	2,147	2,002	1,668	1,490	1,475	1,339	1,293	1,334	1,210	1,184	1,140	1,149	1,128	1,089	1,247	1,007	875	896	789	898	922	908	812	804	688	627	479	396	0	0	0	0	0
Selling, general and administrative
23,564	22,005	21,765	19,698	21,315	20,874	19,639	19,173	16,563	14,914	14,828	13,393	12,505	11,808	8,816	8,376	7,377	6,922	6,864	6,405	5,987	5,553	4,204	3,652	3,044	2,576	2,334	2,006	1,698	1,354	1,274	0	0	0	-	-	-
General and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Change in fair value of management and incentive units
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Total expenses
37,622	36,559	35,375	31,750	31,879	30,599	28,203	26,258	22,516	19,474	18,645	17,780	17,401	17,066	14,329	13,592	12,281	11,882	11,698	11,013	10,009	8,881	6,491	5,461	5,238	5,224	5,482	5,407	4,990	4,514	4,436	4,485	0	0	0	0	0
Loss from operations
-17,167	-18,974	-19,128	-16,211	-16,768	-15,584	-13,804	-13,243	-11,386	-9,842	-10,607	-10,603	-10,959	-11,492	-9,584	-9,590	-9,130	-9,303	-9,532	-8,865	-8,001	-6,892	-5,005	-4,401	-4,445	-4,713	-4,521	-4,243	-3,845	-3,490	-3,903	0	0	0	-	-	-
Other expense:
Gain on disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Gain on extinguishment of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Interest expense, net
-1,134	-1,033	-918	-801	-1,427	-1,461	-1,515	-1,584	-867	-749	-617	-481	-356	-231	-111	9	10	9	10	-39	-170	-310	-434	-472	-353	-422	-416	-382	-411	-564	-951	-1,127	0	0	0	0	0
Loss on foreign currency transactions
-625	-350	-1,292	-445	-1,536	-784	-311	146	1,659	1,454	687	412	-436	-358	-15	-18	172	-507	-518	-609	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Penalties associated with non-registration of Series A Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Change in warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	415	-3,371	-	1,509	503	4,442	2,118	-208	26	-316	0	0	0	0	-	-	-	-	-	-	-	-
Total other expense, net
-1,759	-1,384	-2,211	-1,247	-2,963	-2,245	-1,826	-1,438	791	705	241	103	-811	-589	-1,116	-1,770	2,209	-497	-1,977	-1,295	-5,447	-2,814	-448	-519	-37	-422	-416	-382	-411	-564	-951	-1,127	0	0	0	0	0
Loss before benefit from income taxes
-18,927	-20,358	-21,339	-17,458	-19,732	-17,830	-15,631	-14,681	-10,594	-9,137	-10,366	-10,499	-11,770	-12,082	-10,701	-11,360	-6,920	-9,801	-11,510	-10,161	-13,449	-9,707	-5,454	-4,920	-4,482	-5,136	-4,938	-4,625	-4,257	-4,055	-4,854	-5,544	0	0	0	0	0
Benefit from income taxes
-1,092	-1,092	-619	-619	-619	-619	-676	-676	-676	-676	-318	-318	-318	-318	-324	-324	-324	-324	-385	-385	-385	-385	-458	-458	-458	-458	-391	-391	-391	-391	0	0	0	0	-	-	-
Dividend, warrant exercise price adjustment
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,266	4,437	3,681	2,923	2,395	2,368	2,473	2,433	2,511	2,605	2,853	0	0	0	0	0
Net loss attributable to common shareholders
-17,834	-19,265	-20,719	-16,839	-19,112	-17,211	-15,290	-14,340	-10,253	-8,796	-10,047	-10,181	-11,452	-11,763	0	0	0	-	-	-	-21,215	-18,588	-9,433	-8,143	-6,947	-7,073	-6,914	-6,706	-6,299	-6,174	-7,460	-8,397	0	0	0	0	0
Basic and diluted net loss per common share
-0.10	-0.13	-0.21	-0.11	-0.15	-0.17	-0.10	-0.19	-0.10	-0.13	-0.07	-0.06	-0.06	-0.18	-0.09	-0.12	-0.07	-	-0.11	-	-0.19	-	-0.22	-	-0.20	-0.72	-0.01	-0.01	-0.01	0.00	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
Weighted average number of shares of common stock outstanding
33,981	32,457	32,365	32,266	31,931	31,917	31,305	30,302	29,351	28,791	28,206	27,953	25,503	25,473	25,444	25,416	25,401	-	25,037	-	24,394	-	12,496	-	10,619	-659,301	242,512	231,583	222,968	212,883	204,438	194,439	181,150	168,230	-	-	-
Net loss
-17,834	-19,265	-20,719	-16,839	-19,112	-17,211	-14,955	-14,004	-9,917	-8,460	-10,047	-10,181	-11,452	-11,763	-10,376	-11,035	-6,596	-9,477	-11,124	-9,775	-13,063	-9,321	-4,996	-4,462	-4,023	-4,677	-4,546	-4,233	-3,865	-3,663	-4,854	-5,544	0	0	0	0	0
Comprehensive loss:
Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.06	-	-	-	-0.27	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05	-	-	-	-0.27	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24,768	-	-	-	12,047	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28,826	-	-	-	12,047	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-17,834	-19,265	-20,719	-16,839	-19,112	-17,211	-14,955	-14,004	-9,917	-8,460	-10,047	-10,181	-11,452	-11,763	-10,376	-11,035	-6,596	-9,477	-11,124	-9,775	-13,063	-9,321	-4,996	-4,462	-4,023	-4,677	-4,546	-4,233	-3,865	-3,663	-4,854	-5,544	0	0	0	0	0
Other comprehensive income (loss):
Currency translation adjustment
541	237	1,086	373	1,285	649	193	-185	-1,458	-1,259	-546	-326	428	314	-22	-11	-233	356	378	546	627	283	42	-34	-40	-43	24	-15	-15	-12	0	0	0	-	-	-	-
Comprehensive loss
-17,293	-19,027	-19,633	-16,465	-17,827	-16,562	-14,761	-14,190	-11,375	-9,720	-10,593	-10,508	-11,023	-11,449	-10,399	-11,047	-6,829	-9,120	-10,746	-9,229	-12,436	-9,037	-4,953	-4,497	-4,064	-4,721	-4,522	-4,249	-3,880	-3,676	0	0	0	-	-	-	-
Weighted average number of shares of common stock outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	159,137	106,250	95,409
Product
Total revenue
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyto Sorb Sales
Total revenue
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Sales
Total revenue
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant
Total revenue
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-